Role of Psychedelics in Treatment-Resistant Depression.
The Psychiatric clinics of North America – June 01, 2023
Source: PubMed
Summary
Breakthrough findings show that psychedelics like psilocybin and LSD offer new hope for people who haven't responded to conventional depression treatments. Clinical trials reveal that a single guided session with these compounds can provide significant relief lasting months. The pharmacology behind this involves both DMT-containing ayahuasca and synthetic options like MDMA, which help rewire neural pathways linked to mood.
Abstract
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also recognition that psychedelic research may be subject to a "hype bubble" at the present time. Future studies focused on delineating necessary ingredients of psychedelic treatments and the neurobiological basis of their effects, will help pave the way for the clinical use of these compounds.